New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials

• Published in: International journal of biological sciences Vol. 18; no. 7; pp. 2775 - 2794
• Main Authors: Jin, Haoer, Qin, Sha, He, Jiang, Xiao, Juxiong, Li, Qingling, Mao, Yitao, Zhao, Luqing
• Format: Journal Article
• Language: English
• Published: Australia Ivyspring International Publisher 01.01.2022
• Subjects: B7-H1 Antigen - metabolism; Carcinoma, Hepatocellular - drug therapy; CD28 Antigens - therapeutic use; CTLA-4 Antigen - therapeutic use; Humans; Immunotherapy - methods; Ligands; Liver Neoplasms - drug therapy; Nivolumab - adverse effects; Programmed Cell Death 1 Receptor - therapeutic use; Review; Tumor Microenvironment; Tumor microenvironment (TME); Programmed cell death protein 1 (PD-1); Immune checkpoint inhibitors (ICIs); Cytotoxic T lymphocyte 4 (CTLA-4); Hepatocellular carcinoma (HCC)
• ISSN: 1449-2288; 1449-2288
• DOI: 10.7150/ijbs.70691

Hepatocellular carcinoma (HCC) is one of the most lethal tumors in China and worldwide, although first-line therapies for HCC, such as atezolizumab and bevacizumab, have been effective with good results, the researches on new therapies have attracted much attention. With the deepening research on tumor immunology, the role and operation mechanism of immune cells in the tumor microenvironment (TME) of HCC have been explained, such as programmed cell death protein 1 (PD-1) binding to ligand could cause T cell exhaustion and reduce IFN-γ T cell secretion, cytotoxic T lymphocyte 4 (CTLA-4) and CD28 mediate immunosuppression by competing for B7 protein and disrupting CD28 signal transduction pathway, which also lays the foundation for the development and application of more new immune checkpoint inhibitors (ICIs). The biological behavior of various immune checkpoints has been proved in HCC, such as PD-1, programmed cell death ligand 1 (PD-L1), CTLA-4 and so on, leading to a series of clinical trials. Currently, FDA approved nivolumab, pembrolizumab and nivolumab plus ipilimumab for the treatment of HCC. However, the treatment of ICI has the disadvantages of low response rate and many side effects, so the combination of ICIs and various other therapies (such as VEGF or VEGFR inhibition, neoadjuvant and adjuvant therapy, locoregional therapies) has been derived. Further studies on immune checkpoint mechanisms may reveal new therapeutic targets and new combination therapies in the future.